Global Biopharmaceutical Fermentation Market is valued at US$ 10.17 Bn in 2023, and it is expected to reach US$ 16.03 Bn by 2031, with a CAGR of 6.11% during the forecast period of 2024-2031.
Global Biopharmaceutical Fermentation Market is valued at US$ 10.17 Bn in 2023, and it is expected to reach US$ 16.03 Bn by 2031, with a CAGR of 6.11% during the forecast period of 2024-2031.
The biopharmaceutical fermentation is important aspect of the pharmaceutical industry, which uses living cells to produce drugs. It is plays important role in manufacturing biologic drugs, vaccines, and therapeutic proteins. Fermentation helps to produce complex molecules through biochemical processes, distinguishing it from traditional chemical synthesis methods. Factors such as rising chronic diseases, aging populations, and biotechnology advancements drive the growth of market.
Download Free Report Sample Pages: https://www.insightaceanalytic.com/request-sample/1410
Recent Developments:
- In December 2022, MilliporeSigma completed the acquisition of Erbi Biosystems, a Massachusetts-based company known for its 2 ml micro-bioreactor platform technology called the Breez. This strategic move enhances MilliporeSigma's upstream portfolio in therapeutic proteins by facilitating scalable cell-based perfusion bioreactor processes ranging from 2 ml to 2000 ll and expediting lab-scale process development.
- In October 2022, Froilabo (Japan) introduced a new series of fully automated lab-scale bioreactors. These bioreactors, complementing their existing line of temperature-controlled laboratory equipment, offer a broad range of applications for academic research, process development, optimization, scale-up, and manufacturing.
List of Prominent Players in the Biopharmaceutical Fermentation Market:
-
- GE Healthcare
- Thermo Fisher Scientific
- Danaher Corporation
- Sartorius StedimBiotech
- Merc
- Eppendorf
- Roche
- Nova Biomedicals
- Lonz
- Becto
- Dickinson and Company
- GEA
- F. Hoffmann-La Roche Ltd
- AntoXa Corporation
- BioPharm Process Associates, LLC
- ZETA GmbH
- 3M Company
Market Dynamics:
Drivers:
The biopharmaceutical fermentation market is being propelled by several key drivers. Firstly, the increasing prevalence of chronic diseases is boosting the demand for biopharmaceuticals, driving market growth. Secondly, advancements in biotechnology, such as genetic engineering and recombinant DNA technology, are enhancing the efficiency and productivity of fermentation processes, driving innovation in the industry.
Additionally, the growing investment in research and development by pharmaceutical companies and government initiatives to promote continuous manufacturing are further fueling market expansion. Moreover, the rising demand for personalized medicine and biologics is creating new opportunities for market players.
Challenges:
The high cost associated with biopharmaceutical fermentation and its installation poses a significant challenge to the growth of the biopharmaceutical fermentation market. Biopharmaceutical fermentation processes often require substantial capital investments in equipment, facilities, and technology. The need for specialized bioreactors, fermentation vessels, and purification systems contributes significantly to the overall cost. This capital intensity can deter potential entrants and limit the expansion of existing facilities.
Regional Trends:
The North American biopharmaceutical fermentation market is anticipated to register a significant revenue share and experience rapid CAGR in the near future is due to advanced infrastructure and technological capabilities. Stringent regulatory standards and quality control measures ensure the safety and efficacy of biopharmaceutical products, instilling confidence in both consumers and investors.
Additionally, the presence of key market players, coupled with robust research and development activities, drives innovation and product development in the region. Furthermore, increasing investments in biotechnology and healthcare infrastructure, along with a growing demand for personalized medicine, continue to propel market growth.
Top of Form
Segmentation of Biopharmaceutical Fermentation Market-
Biopharmaceutical Fermentation Market- By Product
- Upstream Process
- Bioreactors/Fermenters
- Bioprocess Analyzers
- Process Monitoring System
- Culture & Media Preparation
- Other Upstream Products
- Downstream Products
- Filtration and Separation
- Chromatography
- Consumables and Accessories
- Other Downstream Products
Biopharmaceutical Fermentation Market- By Application
- Recombinant Proteins
- Monoclonal Antibodies
- Antibiotics
- Probiotics
- Others
Biopharmaceutical Fermentation Market- By End-User
- Biopharmaceutical Companies
- Contract manufacturing Organizations
- Contract Research Organizations
- Academic Research Institutes
- Food Industry
- Others
Biopharmaceutical Fermentation Market- By Distribution Channel
- Direct Distribution
- Indirect Distribution
Biopharmaceutical Fermentation Market- By Region
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Order the 180 Pages Detailed Report @ https://www.insightaceanalytic.com/buy-report/1410
Call: North America +1 551 226 6109 Email: diana.dsouza@insightaceanalytics.com